A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Lung CancerNSCLCNon-Small-Cell Lung Cancer
Interventions
DRUG

ABT-751

200 mg ABT-751 daily for 14 days every 21 days

DRUG

pemetrexed

Standard pemetrexed every 21 days

DRUG

placebo

Placebo daily for 14 days every 21 days

Trial Locations (48)

3529

Site Reference ID/Investigator# 3333, Miskolc

8000

Site Reference ID/Investigator# 3332, Székesfehérvár

11042

Site Reference ID/Investigator# 5098, Lake Success

18015

Site Reference ID/Investigator# 3354, Bethelem

19141

Site Reference ID/Investigator# 6006, Philadelphia

20817

Site Reference ID/Investigator# 2401, Bethesda

21229

Site Reference ID/Investigator# 2416, Baltimore

28078

Site Reference ID/Investigator# 2242, Huntersville

30309

Site Reference ID/Investigator# 3807, Atlanta

33316

Site Reference ID/Investigator# 2411, Fort Lauderdale

33805

Site Reference ID/Investigator# 3363, Lakeland

34952

Site Reference ID/Investigator# 3352, Port Saint Lucie

37620

Site Reference ID/Investigator# 2414, Bristol

43235

Site Reference ID/Investigator# 2413, Columbus

46256

Site Reference ID/Investigator# 3359, Indianapolis

49048

Site Reference ID/Investigator# 2075, Kalamazoo

54007

Site Reference ID/Investigator# 3403, Thessaloniki

56403

Site Reference ID/Investigator# 3406, Thessaloniki

60637

Site Reference ID/Investigator# 3353, Chicago

62500

Site Reference ID/Investigator# 4687, Brno

65109

Site Reference ID/Investigator# 2418, Jefferson City

69733

Site Reference ID/Investigator# 4278, Kyjov

71110

Site Reference ID/Investigator# 3405, Heraklion

71913

Site Reference ID/Investigator# 4102, Hot Springs

72703

Site Reference ID/Investigator# 3358, Fayetteville

80524

Site Reference ID/Investigator# 2417, Fort Collins

94904

Site Reference ID/Investigator# 2127, Greenbrae

98405

Site Reference ID/Investigator# 2070, Tacoma

06790

Site Reference ID/Investigator# 5690, Torrington

21231-1000

Site Reference ID/Investigator# 2244, Baltimore

01960

Site Reference ID/Investigator# 3793, Peabody

01608

Site Reference ID/Investigator# 3362, Worcester

63110-0250

Site Reference ID/Investigator# 4170, St Louis

03756

Site Reference ID/Investigator# 3357, Lebanon

656 53

Site Reference ID/Investigator# 3337, Brno

741 01

Site Reference ID/Investigator# 3328, Nový Jičín

775 20

Site Reference ID/Investigator# 3327, Olomouc

708 52

Site Reference ID/Investigator# 3343, Ostrava-Poruba

128 08

Site Reference ID/Investigator# 3344, Prague

140 59

Site Reference ID/Investigator# 3342, Prague

262 04

Site Reference ID/Investigator# 3411, Příbram

H-1529

Site Reference ID/Investigator# 3331, Budapest

1081 HV

Site Reference ID/Investigator# 3409, Amsterdam

5623 EJ

Site Reference ID/Investigator# 3319, Eindhoven

3844 DG

Site Reference ID/Investigator# 3341, Haraderwijk

1624 NP

Site Reference ID/Investigator# 3528, Hoorn

826 06

Site Reference ID/Investigator# 3400, Bratislava

036 59

Site Reference ID/Investigator# 3410, Martin

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00297089 - A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter